Skip to main content
Premium Trial:

Request an Annual Quote

Intrexon Buying Medistem for $26M

NEW YORK (GenomeWeb News) – Intrexon today announced an agreement to acquire adult stem cell technology firm Medistem for about $26 million.

Based in San Diego, Medistem develops endometrial regenerative cells, which are universal donor adult stem cells that stimulate new blood vessel formation. ERCs can generate different tissues such as heart, brain, pancreas, liver, bone, cartilage, and lung, and Intrexon plans to use its synthetic biology platforms to "engineer a diverse array of cell-based therapeutic candidates using Medistem's multipotent ERCs," it said.

Medistem's ERCs combined with Intrexon's technologies, including the UltraVector multi-gene engineering system, "have the potential to provide treatments for conditions such as cancer, wound healing, and cardiovascular disease," the Germantown, Md.-based company added.

Under the terms of the agreement, Medistem's shareholders will receive, in exchange for each share of Medistem common stock, $.27 in cash and $1.08 worth of Intrexon common stock.

"We look forward to further refining ERCs to produce proteins and bioactive RNAs, both of which hold great promise to be used as therapeutics to treat conditions, such as cardiovascular disease and cancer," Samuel Broder, Intrexon's Health Sector, said in a statement. "Through the use of our synthetic biology platforms, we anticipate unlocking the power of ERCs to safely advance therapeutic development from proof of concept to clinical research."

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.